STOCK TITAN

Pasithea Therapeutics Corp. - KTTA STOCK NEWS

Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.

Pasithea Therapeutics Corp. (symbol: KTTA) is a forward-thinking biotechnology company dedicated to the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. By leveraging advancements in the fields of neuroscience, translational medicine, and drug development, Pasithea Therapeutics aims to address unmet medical needs and improve patient outcomes.

The company's robust pipeline includes promising treatments for Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. These conditions represent significant therapeutic challenges, and Pasithea Therapeutics is committed to advancing research to bring effective solutions to market.

Recent achievements highlight the company's progress in translating scientific discoveries into potential therapeutic applications. Notably, initial safety, tolerability, and biomarker data are expected to be reported in the second half of 2024. This milestone will be crucial in validating the efficacy of their treatments and guiding future development.

As a driver of innovation in biotechnology, Pasithea Therapeutics collaborates with leading researchers, healthcare providers, and institutions to enhance its research capabilities and expedite the drug development process. Strategic partnerships play a pivotal role in the company's ability to stay at the forefront of scientific advancements and bring new therapies to patients in need.

The financial condition of Pasithea Therapeutics is underscored by its commitment to transparency and robust corporate governance. The company continuously strives to maintain a solid financial foundation to support its research and development activities.

Stay updated with the latest news and developments from Pasithea Therapeutics by checking their regular press releases and corporate communications. For more information, please contact Patrick Gaynes, Corporate Communications, at pgaynes@pasithea.com.

Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its Chairman, Prof. Lawrence Steinman, will receive the 2023 Pioneer in Medicine Award for significant contributions to brain mapping and therapeutics at the 20th Annual Gathering for the Cure on February 17, 2023. This award is presented by the Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping Foundation, recognizing pioneering work in fields like multiple sclerosis (MS). The company is focusing on developing a proprietary engineered DNA plasmid vaccine, PAS-002, targeting GlialCAM for MS treatment, affecting over 2.3 million people worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
none
-
Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced a partnership with WuXi STA to manufacture the active pharmaceutical ingredient for its MEK Inhibitor PAS-004, targeting Neurofibromatosis Type 1 (NF1). This collaboration is pivotal as the company aims to submit its Investigational New Drug (IND) application to the FDA in the second half of 2023, following successful pre-clinical testing. PAS-004 has received orphan drug designation and is expected to commence a Phase 1 clinical trial soon. WuXi STA is recognized for meeting rigorous global quality standards, reinforcing the development of PAS-004 into a promising therapeutic option for CNS disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced the results of its Special Meeting of Stockholders held on December 9, 2022. Approximately 67% of stockholders voted against proposals to remove the current Board of Directors, representing about 12.7 million shares or 44% of total shares. This decision allows the current Board to continue overseeing the company's strategy. CEO Dr. Tiago Reis Marques expressed gratitude for stockholder support and commitment to developing innovative treatments for CNS disorders, including ALS and Multiple Sclerosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
Rhea-AI Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) has reached a Settlement and Cooperation Agreement with the Camac Group, resolving all litigation issues. The Camac Group will observe a three-year standstill and has agreed to sell 3,205,282 shares of common stock at $1.0003 each, reflecting the five-day average price. Pasithea will also reimburse certain expenses. CEO Tiago Reis Marques expressed optimism about this agreement, stating it allows the company to focus on advancing its CNS therapies. The Board of Directors will continue overseeing the company's strategy following a recent Special Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
none
-
Rhea-AI Summary

Pasithea Therapeutics (NASDAQ: KTTA) has announced its preclinical data for PAS-003, a monoclonal antibody targeting Alpha 5 Beta 1 integrin as a potential treatment for amyotrophic lateral sclerosis (ALS) and related CNS disorders. The presentation will occur on December 7th at the Antibody Engineering & Therapeutics Conference in San Diego, by Dr. Lawrence Steinman, Chairman of Pasithea. PAS-003 has demonstrated significant improvements in SOD1 mouse models, indicating its promise in improving clinical outcomes for ALS patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
conferences
-
Rhea-AI Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) has postponed its Special Stockholder Meeting from November 29, 2022, to December 9, 2022, at 9:00 am ET. This decision allows more time for stockholder voting proxies. The meeting will still address the proposals submitted by a Dissident Group, which includes several investment firms and individuals. The record date remains November 9, 2022. Pasithea is focused on innovative treatments for CNS disorders, including ALS and Multiple Sclerosis, leveraging its expertise in neuroscience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
Rhea-AI Summary

Camac Partners and affiliates, the largest external stockholder of Pasithea Therapeutics Corp. (NASDAQ: KTTA), are advocating for the removal of the Company’s Board of Directors. This call to action comes ahead of the Special Meeting scheduled for November 29. The Investor Group criticizes the Board for its management decisions and perceived disenfranchisement of stockholders, urging fellow investors to support their proposals using the WHITE proxy card.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
none
-
Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its Chairman, Prof. Lawrence Steinman, will present results from a preclinical study on their tolerizing vaccine PAS002 for multiple sclerosis at the Immunotherapy 2022 Symposium in Buenos Aires from Oct. 14-17, 2022. Prof. Steinman and Nobel laureate Dr. James Allison will receive honorary doctorates from the University of Buenos Aires. CEO Dr. Tiago Reis Marques expressed excitement about sharing their findings and their commitment to developing effective neurological treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.2%
Tags
conferences
-
Rhea-AI Summary

Camac Partners, LLC and affiliates condemn Pasithea's decision to pursue a second dilutive acquisition of AlloMek Therapeutics within six months, disregarding stockholder feedback. The Investor Group, the largest stockholder in Pasithea Therapeutics Corp. (KTTA), emphasizes the need for a Special Meeting to address investor dissatisfaction with the Board's decisions. The group seeks to investigate the recent acquisitions and stresses that these moves do not align with stockholder interests.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Pasithea Therapeutics has acquired AlloMek Therapeutics for $1.05 million in cash, 2.7 million shares, and warrants for an additional 1 million shares. The acquisition aims to enhance Pasithea's CNS product portfolio with CIP-137401, a next-generation MEK inhibitor designed for treating neurofibromatosis type 1 (NF1) and Noonan syndrome. The FDA has granted orphan-drug designation for CIP-137401. An IND application is expected to be filed in the second half of 2023, followed by Phase 1 trials. The acquisition supports long-term growth and potential synergies with existing programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags

FAQ

What is the current stock price of Pasithea Therapeutics (ktta)?

The current stock price of Pasithea Therapeutics (ktta) is $3.8 as of November 1, 2024.

What is the market cap of Pasithea Therapeutics (ktta)?

The market cap of Pasithea Therapeutics (ktta) is approximately 3.9M.

What does Pasithea Therapeutics Corp. specialize in?

Pasithea Therapeutics Corp. specializes in the discovery, research, and development of treatments for central nervous system (CNS) disorders and RASopathies.

What diseases are included in Pasithea Therapeutics' pipeline?

The pipeline includes treatments for Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

When is the initial safety and biomarker data expected to be reported?

The initial safety, tolerability, and biomarker data are expected to be reported in the second half of 2024.

Who can be contacted for more information about Pasithea Therapeutics?

For more information, you can contact Patrick Gaynes, Corporate Communications, at pgaynes@pasithea.com.

How does Pasithea Therapeutics advance its research?

Pasithea Therapeutics advances its research through collaborations with leading researchers, healthcare providers, and institutions, focusing on innovation in neuroscience and translational medicine.

What is the significance of Pasithea Therapeutics' work?

Pasithea Therapeutics' work is significant in addressing unmet medical needs and improving patient outcomes for complex CNS disorders and other diseases.

Does Pasithea Therapeutics provide regular updates?

Yes, Pasithea Therapeutics provides regular updates through press releases and corporate communications.

What are the core areas of research for Pasithea Therapeutics?

The core areas of research include treatments for CNS disorders, leveraging neuroscience and drug development to address conditions like ALS, MS, and Schizophrenia.

What are RASopathies?

RASopathies are a group of disorders caused by mutations in the RAS gene, affecting cell growth and development, which Pasithea Therapeutics aims to treat through their innovative research.

How does Pasithea Therapeutics support its financial stability?

Pasithea Therapeutics supports its financial stability through transparent corporate governance and maintaining a solid financial foundation to back its research and development activities.

Pasithea Therapeutics Corp.

Nasdaq:KTTA

KTTA Rankings

KTTA Stock Data

3.92M
1.05M
23.12%
2.87%
2.18%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
VENICE